survival (PFS) and better life quality than chemotherapy in advanced NSCLC patients with EGFR mutations in many clinical trials, [3] [4] [5] [6] [7] [8] [9] [10] in which most of the patients were adenocarcinoma. However, the efficacy of EGFR-TKIs in patients with lung SCC is limited, even in SCC patients with EGFR mutations. EGFR mutation testing was an essential part of standard care for lung cancer. Several societies have issued guidelines and consensus statements regarding EGFR mutation testing in patients with lung SCC. According to the American Society of Clinical Oncology (ASCO), none of the patients with NSCLC should be excluded from having the EGFR genetic testing performed if the patient is being considered for first-line therapy with an EGFR-TKI and the decision is physician-driven. 11 In Europe, the consensus of the European Society for Medical Oncology (ESMO) suggests that EGFR mutation testing should be performed in patients who are never/former light smokers and in patients with nonsquamous cell carcinoma. 12 The consensus guideline from the College of American Pathologist (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) suggests EGFR mutation testing in lung ADC, in tumors where an ADC component cannot be excluded, and in cases, whose clinical criteria are unusual. 13 The National Comprehensive Cancer Network (NCCN) guideline adopts the idea and suggests the consideration of EGFR mutation testing in lung SCC especially in never smokers, small biopsy specimens, or mixed histology. 14 In summary, ASCO recommends EGFR mutation testing in all patients with SCC when EGFR-TKIs are considered, but ESMO/ACP/IASLC/AMP/NCCN suggests it only in some specific conditions. In recent years, several prospective and retrospective studies have demonstrated that the frequency of EGFR mutations in patients with SCC was 3.9%-17.2%, which was higher than expected. [15] [16] [17] However, the efficacy of EGFR-TKIs in EGFR-mutated lung SCC is still controversial, and the tumor responses in SCC are much lower than the ORR in EGFR-mutated lung SCC (n = 27) and ADC (n = 199) with gefitinib was 30% and 66%, respectively (P < 0.001). Wu et al 19 found the objective response rate (ORR) in EGFR-mutated nonadenocarcinoma (n = 9) and ADC (n = 161) with gefitinib or erlotinib was 22.2% and 69.6%, respectively (P = 0.003). Icotinib, an orally administered EGFR-TKI with high selectivity, has been used widely in China. In a Phase 3 randomized head-to-head trial (ICOGEN), 20 icotinib was clinical equivalent to gefitinib in patients with NSCLC. The efficacy of icotinib for patients with SCC is not well known.
In this study, we decided to investigate the efficacy of icotinib in both unselected and EGFR-mutated advanced lung SCC population
| PATIENTS AND METHODS

| SCC patients
Advanced unselected or EGFR-mutated lung SCC patients treated with icotinib were retrospectively selected from expand access program (EAP) database of Betta The inclusion criteria were pathologically confirmed locally advanced stage IIIB or metastatic stage IV SCC of the lung after at least 5 months treatment of icotinib before charity period, because patients were from EAP database. The exclusion criteria were as follows: (a) icotinib used as adjuvant therapy; (b) icotinib combined with chemotherapy; and (c) data were incomplete. The institutional ethnic commitment board of the Peking Union Medical College Hospital approved the study. All patients provided written informed consent before participation in the charity project.
| Matching adenocarcinoma patients
There were 289 EGFR-mutated lung adenocarcinoma patients from EAP database of Betta Pharmaceuticals were selected to have 1:1 ratio of propensity score matching with EGFR-mutated lung SCC patients. The propensity scores, which were calculated from the logistic regression models, included the following variables: age, gender, clinical stage, KPS, smoking history, EGFR mutation type, and treatment lines. Through the matching procedure for propensity scores, the EGFR-mutated SCC and EGFRmutated ADC groups showed similar distributions of propensity scores, indicating that the differences in covariates between the two groups were minimized. We matched propensity scores one by one using nearest neighbor methods, no replacement, and 0.03 clipper width. Finally, we matched 78 patients from EGFR-mutated SCC group and 78 patients from EGFR-mutated ADC group.
| Test method for EGFR mutations
Mutations in the tyrosine kinase domain of EGFR were identified using the amplification refractory mutation system (ARMS). DNA was extracted from patients' fresh tissue or paraffin-embedded tissue. Not all patients with lung SCC were included in the EGFR mutation analysis.
| Clinical assessments
Patients received 125 mg oral icotinib three times per day, a treatment cycle is 28 days until intolerable toxicity disease progression or death. According to EAP program, first-time tumor imaging and routine laboratory test were performed 4 weeks after therapy, repeated every 8 weeks. The objective tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). 21 Objective tumor responses included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Disease control rate (DCR) was defined as the addition of objective response and stabilization. The PFS was calculated from the date of initiation of icotinib therapy to the date of tumor progression or any cause of death. The duration of overall survival (OS) was calculated from the date of initiation of icotinib therapy to the date of death. Figure 1 . The characteristics (age, gender, clinical stage, KPS, smoking history, EGFR mutation type, and treatment lines) of all patients were well balanced among groups and are summarized in Table 1 .
| Statistical methods
| Efficacy
The PFS for unselected lung SCC patients (n = 487) was 13.0 months (95% CI 12.2-13.8), and OS was 16.0 months (95% CI 14.7-17.3) (Figure 2A,B) . Univariate analysis of unselected lung SCC patients PFS showed that patients with better KPS score and objective tumor response to icotinib had significant longer PFS ( Figure 2C ,E, Table 2 ), but in multivariate analysis, only objective tumor response had significant lower HR (Table 2 ). Both univariate analysis and multivariate analysis of unselected lung SCC patients OS demonstrated that better KPS score and objective tumor response to icotinib had significant better OS (Figure 2D ,F; Table 2 ). Among EGFR-mutated SCC (n = 78) and matching ADC (n = 78) patients, no significant difference in PFS and OS was found between the two groups ( Figures 3A and 4A The incidence of adverse events of icotinib was low in all groups, and the most common adverse events were rash, diarrhea, and raised transaminase (Table 3) .
| DISCUSSION
EGFR mutation rate was low in lung SCC, and data of efficacy of EGFR-TKIs for patients with lung SCC are limited. Some studies have argued that response to EGFR targeted therapies in SCC is contributed to pathological mis-classification, 22 and it is also increasingly being recognized that different mutation testing systems have different sensitivity variations for detection of EGFR mutations. 23 In BR.21and SATURN clinical trials, subgroup analysis showed that treatment with EGFR-TKIs was effective in patients with SCC. 24, 25 A meta-analysis demonstrated that EGFR-TKIs prolonged PFS and OS (P = 0.004, P = 0.04) compared with placebo in unselected patients with advanced lung SCC. 26 But more trials reported that EGFR-TKIs were less effective in patients with SCC, even in EGFR-mutated SCC patients. Hata et al 27 found that the ORR was 9.7%, DCR was 43.9%, median PFS was 2.2 months (95% CI 1.0-2.8), and median OS was 11.0 months (95% CI 5.7-15.7) in unselected lung SCC (n = 41) treated with erlotinib. Tseng et al 28 found the ORR was 17.4%, DCR was 27.2%, median PFS was 1.7 months (95% CI 1.4-2.0), and median OS was 4.4 months (95% CI 2.8-7.1) in unselected lung SCC (n = 92)
T A B L E 3 Most common adverse events
Unselected SCC (n = 487) treated with erlotinib. In our study, the ORR and DCR in unselected lung SCC (n = 487) were 41.3% and 99.8%, and the median PFS and OS were 13.0 months (95% CI 12.2-13.8) and 16 .0 months (95% CI 14.7-17.3), respectively. The favorable efficacy of EGFR-TKIs in our study should be considered in the context that these patients with SCC had nonprogressive disease after 5-month treatment of icotinib, which enriched the responsive patients. The results in the present study showed that SCC patients with objective responses had better PFS and OS benefits than those without responses, suggesting that patients with lung SCC have a better tumor response to EGFR-TKIs would have a better prognosis. Better PFS and OS benefits were also seen in unselected lung SCC patients with a KPS ≥80 compared with those with a KPS 60-80. Performance status is an independent predictive factor of icotinib treatment outcome in unselected advanced lung SCC patients. This may provide a trend for clinician to choose EGFR-TKIs treatment in patients with advanced lung SCC.
EGFR-mutated SCC (n = 78)
EGFR-mutated ADC (n = 78)
ADC patients with sensitizing EGFR mutations may survival about 30 months. However, controversial efficacy of EGFR-TKIs was seen in EGFR-mutated SCC patients. The OPTIMAL trial demonstrated that erlotinib was associated with a better PFS benefit for patients with EGFR mutations than standard chemotherapy, 7 irrespective of histologic type, whereas there were only 10 nonadenocarcinoma patients enrolled in the erlotinib group. In the pooled analysis of Shukuya et al, 18 the median PFS in EGFR-mutated SCC (n = 27) and ADC (n = 199) with gefitinib was 3.1 months vs 9.4 months (P = 0.0001), and the ORR was 30% vs 66%, respectively (P < 0.001). In the pooled analysis of Wu et al, 19 the median OS in EGFR-mutated nonadenocarcinoma (n = 9) and ADC (n = 161) with gefitinib or erlotinib was 2.3 months vs 18.1 months (P < 0.001), and the ORR was 22.2% vs 69.6%, respectively (P = 0.003). A retrospective matched-pair case-control study 29 found
EGFR-mutated SCC (n = 44) and ADC (n = 44) patients with EGFR-TKIs had similar ORR (43.2% vs 54.5%, P = 0.290), but patients with SCC had lower DCR (71.3% vs 100%, P = 0.001), significant shorter median PFS (5.1 vs 13.0 months, P = 0.000), and median OS (17.2 vs 23.6 months, P = 0.027). In summary, benefits of EGFR-TKIs in EGFR-mutated SCC patients are inferior to EGFR-mutated ADC patients; however, unmatched EGFR-mutated SCC and ADC patients may lead to bias, and the sample size of EGFR-mutated SCC patients was very small. In this study, we collected 78 EGFR-mutated SCC patients and matched with ADC patients to compare the efficacy of EGFR-TKIs, and the results showed that median PFS in EGFR-mutated SCC and ADC patients treated with icotinib was 12.7 months vs 15.8 months, median OS was 18.5 months vs 24.2 months, and the ORR was 48.7% vs 59.0%. No significant difference was detected between the two groups in PFS or OS.
In recent years, there are several molecularly targeted agents, and immunotherapies have provided a new level of optimism for patients with lung SCC. Anti-EGFR monoclonal antibodies (necitumumab 30 and cetuximab [31] [32] [33] ) in combination with standard chemotherapy significantly improved lung SCC patients' survival time with an acceptable safety profile. The immune-checkpoint inhibitors nivolumab 34 and pembrolizumab 35 have demonstrated durable tumor responses and encouraging survival improvements vs standard cytotoxic agents. The anti-VEGFR2 antibody ramucirumab has been approved in combination with docetaxel for the second-line treatment of NSCLC, including lung SCC, based on the Phase III REVEL trial. 36 The ErbB-family blocker afatinib has demonstrated clinical activity in patients with lung SCC. 10, 37, 38 Afatinib significantly improved the PFS, OS, and DCR vs erlotinib in the LUX-Lung 8 trial, 39 leading to its approval for locally advanced or metastatic lung SCC who had progressed after platinum-based chemotherapy. The future for the treatment of lung SCC is increasingly promising, and we look forward to further developments in the coming years.
The results of the present study should be interpreted with the consideration of several limitations. The major limitation of this study was its retrospective nature, which had selection bias to a certain degree. Second, the small sample size in EGFR-mutated SCC and ADC patients would affect the statistical analysis. Third, the present study could not obtain immunohistochemical results of all patients with SCC; therefore, we could not distinguish poorly differentiated adenocarcinoma. Some experts hold the view that some EGFR-mutated SCC patients may also have a mixed ADC histology, and the sensitivity of EGFR-TKIs in these patients might depend on the proportion of EGFR-mutated ADC components in the whole tumor. 40, 41 World Health Organization recommends immunohistochemistry not only for small biopsies/cytology, but also for resected specimens in certain settings such as solid ADC, nonkeratinization SCC, which guides the treatment. 42 Furthermore, since the retrospective nature, the incidence of adverse events during the medication was lower than the actual situation. Prospective study with large sample was needed to over limitations mentioned above.
In conclusion, icotinib has some effects in unselected and EGFR-mutated SCC patients as in ADC patients, who had received at least 5 months of icotinib treatment. Icotinib should be considered as a potential treatment option for this patient population, and EGFR mutation test should be recommended in all patients with SCC.
